双歧杆菌三联活菌散联合三联疗法在幽门螺杆菌感染慢性胃炎的应用研究

目的 探讨双歧杆菌三联活菌散联合三联疗法治疗幽门螺杆菌(Hp)感染的慢性胃炎的临床疗效及安全性。 方法 选取2015年3月-2016年3月湖州市中心医院消化内科收治的Hp感染的慢性胃炎患者178例,按随机数字表法分组,对照组89例予以三联疗法治疗,研究组89例在对照组基础上予以双歧杆菌三联活菌散治疗,观察2组间临床症状评分、血清胃泌素水平相关指标,对比分析2组的疗效。 结果 对照组总有效率(84.27%)显著低于研究组(95.51%),差异有统计学意义;与对照组比较,研究组治疗后胃胀胃痛、口干口苦、嗳气、吞酸、嘈杂症状评分较低,治疗后血清白细胞介素-8(IL-8)、白细胞介素-17(IL-17)、白细胞介素-6(IL-6)、转化生长因子-β1(TGF-β1)水平较低,治疗后血清胃泌素17(G17)、胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)水平较低,差异均具有统计学意义(均P<0.05);治疗中出现的不良反应主要有恶心、呕吐、头晕、腹泻等,研究组不良反应发生率(4.49%)明显低于对照组(13.48%),2组差异有统计学意义。 结论 双歧杆菌三联活菌散联合三联疗法治疗Hp感染的慢性胃炎临床疗效确切,能有效减轻临床症状,降低血清细胞因子水平,抑制胃泌素17及胃蛋白酶释放,安全性较高。 

Application of triple viable bifidobacterium powder combined with triple therapy in chronic gastritis with Helicobacter pylori infection

Objective To investigate the clinical efficacy and safety of Bifidobacterium triad combined with triple therapy in the treatment of chronic gastritis with Helicobacter pylori (Hp) infection. Methods Total 178 cases of chronic gastritis with Hp infection in our hospital were selected and randomly divided into control group (89 cases, treated with triple therapy) and study group (89 cases, received additional Bifidobacterium triple viable powder). The clinical symptom score and serum gastrin level were observed, the curative effect was compared between the two groups. Results The total efficiency of the control group was 84.27% and of the study group was 95.51%, the difference was statistical significant. After the treatment, the score of stomachache and stomach bloating, dryness and bitterness of the mouth, belching and acid regurgitation in the study group were lower when compared with the control group; the levels of serum interleukin-8(IL-8), white interleukin-17(IL-17), interleukin -6(IL-6), transforming growth factor beta 1 (TGF-beta 1), serum gastrin in 17(G17), pepsinogen Ⅰ(PG Ⅰ) adn pepsinogen Ⅱ (PG Ⅱ) of the study group were lower when compared with the control, the difference was statistical significant (P<0.05); The main adverse reactions during the treatment were nausea, vomiting, dizziness, diarrhea, the incidence of adverse reactions in the study was 4.49%, which was significantly less than the control group (13.48%), the difference was statistical significant. Conclusion Bifidobacterium triple viable powder combined with triple therapy is effective in the treatment of chronic gastritis with Hp infection. It can effectively reduce the clinical symptoms, reduce serum cytokines levels, and inhibit gastrin 17 and pepsin release, with high safety.